Senzime

Senzime is a Swedish public company on a mission to eradicate the complications of residual neuromuscular blockade (rNMB) through quantitative monitoring. Its core achievement is the development and commercialization of the TetraGraph® system, a novel train-of-four (TOF) monitor that provides objective, numerical data to guide anesthesia care. The company's strategy focuses on driving clinical adoption in key markets like the US and Europe, supported by a growing body of evidence linking its technology to improved patient outcomes and hospital economics. Senzime aims to establish quantitative neuromuscular monitoring as a new standard of care in anesthesia.

Senzime's platform is based on quantitative neuromuscular transmission (NMT) monitoring using acceleromyography. Its flagship TetraGraph® system provides an objective, numerical train-of-four (TOF) ratio to precisely guide the administration and reversal of neuromuscular blocking agents during anesthesia.

Senzime competes primarily against qualitative monitoring modules from large players like Medtronic and GE Healthcare, as well as other quantitative specialists. Its competitive edge stems from a dedicated focus, user-friendly design, and a growing body of clinical evidence supporting its technology's impact on patient outcomes.